Lyon’s Léon Bérard Centre Pioneers New Treatment for Aggressive Brain Cancers
Lyon, May 19 – The Léon Bérard Centre in Lyon, a leading institution in the fight against cancer, has launched a new clinical trial, Tarlatem, to combat aggressive brain cancers. This innovative strategy aims to address the critical lack of effective treatments for recurrent forms of these highly aggressive tumors.
Brain cancer is a rare disease, affecting less than 1% of the population, yet it is often associated with a poor prognosis and impacts patients of all ages, from children to the elderly, as explained by the cancer research center to actu Lyon.
Addressing a Critical Need for Recurrent Tumors
Dr. Pierre Leblond, the study coordinator, emphasized the urgent need for new therapeutic approaches. “There is currently a lack of active treatment in cases of recurrence of these highly aggressive tumors, so it is necessary to introduce new agents and imagine new strategies,” he stated.
The Tarlatem trial will combine two complementary treatments: Tarlatamab, an innovative immunotherapy that helps the immune system identify and attack cancer cells, and Temozolomide, a well-established chemotherapy for brain tumors, administered at a low, continuous dose. This metronomic treatment aims to gradually modify the tumor’s environment, making the immune system more receptive to the immunotherapy.
Patient Eligibility and Future Inclusions
Eligibility for the Tarlatem trial is specific, requiring patients to have a high-grade DLL3-positive tumor. The trial is expected to include approximately one hundred patients across fifteen centers in France, encompassing various types of high-grade brain tumors in both adults and children. Inclusions for pediatric patients are anticipated to begin by the end of 2026.
Broader Impact and Ongoing Research
This initiative underscores the Léon Bérard Centre’s commitment to advancing cancer treatment and offering new hope to patients facing aggressive brain cancers. The combination of immunotherapy and metronomic chemotherapy represents a significant step forward in personalized medicine, targeting specific tumor characteristics to enhance treatment efficacy.
The centre continues to be at the forefront of medical innovation, as evidenced by recent successes such as a surgeon performing a previously unattempted cancer operation in Lyon, hailed as an “innovative gesture.” Such advancements highlight the dynamic research environment and dedication to patient care within the institution.
The Tarlatem trial is a testament to the ongoing efforts to improve outcomes for patients with brain tumors, a disease that, despite its rarity, presents significant challenges due to its aggressive nature and limited treatment options, especially in cases of recurrence.
Source: https://actu.fr/auvergne-rhone-alpes/lyon_69123/lyon-le-centre-leon-berard-experimente-un-traitement-inedit-contre-ce-cancer-rare-et-agressif_64280726.html
